The problem of those with Parkinson’s disease becoming addicted to dopamine replacement therapy is well know, but it’s also now emerging that some patients have trouble coming of dopamine agonists.

Margarita Pondal, from the Movement Disorders Centre, University of Toronto, talks us through her study looking at the prevalence of the syndrome, and the patients who are most likely to be affected.

See also:
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’